Benzinga | Aug 3, 2020 07:38AM EDT

Ligand Pharmaceuticals Raises FY2020 Adj EPS Guidance from $3.65 to $4.10 vs $3.71 Est; Raises FY2020 Sales Guidance from $140.00M to $165.00M vs $142.45M Est

Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2020 Adj EPS guidance from $3.65 to $4.10 vs $3.71 analyst estimate. Raises FY2020 sales outlook from $140.00 million to $165.00 million vs $142.45 million estimate.